Call for Abstract

International Conference on Clinical Trials, will be organized around the theme “A Conclave for Transformation of Antiquated Treatment and Healthcare Therapeutics”

Clinical Trials-2015 is comprised of 10 tracks and 67 sessions designed to offer comprehensive sessions that address current issues in Clinical Trials-2015.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Pre-clinical research also named preclinical studies and nonclinical studies is a stage of research that begins before clinical trials, and during which important feasibility, iterative testing and drug safety data is collected. More than 600 clinical research centers are there worldwide, and approximately 1500 universities in which pre-clinical and clinical researches are going on. Clinical research funded by government grants like National Science Foundation, the National Institutes of Health, etc., companies doing research and development, and non-profit foundations like the Breast Cancer Research Foundation. According to Pharma Clinical Trial Services: World Market 2011-2021. Global revenues are expected to reach US$32.73 billion in 2015 and to exceed US$65 billion in 2021, with the top ten CRO’s then accounting for more than half of the overall market.
  • Track 1-1Phases of clinical trials
  • Track 1-2Innovations in patient and community engagement in clinical trials
  • Track 1-3Clinical study designs
  • Track 1-4Data monitoring for trials with an adaptive design
  • Track 1-5Heterogeneity of treatment effect in randomized clinical trials
  • Track 1-6Treating different ailments by clinical trials
  • Track 1-7Pre-clinical research leading to clinical trials
The process of identification, analysis and either acceptance or mitigation of uncertainty in investment decision-making Essentially, risk management occurs anytime an investor or fund manager analyzes and attempts to quantify the potential for losses in an investment and then takes the appropriate action given their investment objectives and risk tolerance. Inadequate risk management can result in severe consequences for companies as well as individuals. A practice used by different companies to reduce costs by transferring portions of work to outside suppliers rather than completing it internally is called Outsourcing. It is a very important tool for reducing cost and improving quality. If an organization does one or all its work by itself, its work may affect its production quality. So, an organization must realize some important areas, from which its cost is reduced and its products stay in high quality.
  • Track 2-1Bayesian data analysis
  • Track 2-2Sequential treatment factors for controlled trials
  • Track 2-3Evaluating complex intervention to improve healthcare
  • Track 2-4Phase I clinical trial design for drug development
  • Track 2-5Pharmacokinetic-Pharmacodynamic for regulatory decision
  • Track 2-6Data management and statistics
Clinical trials for the development of a new drug are, for the most part, initiated and financed by industry. There are also many clinical trials initiated by academic clinical researchers. Whether initiated by industry or by academic clinical investigators, clinical research is often performed in national, European and worldwide consortia, which can sometimes be very large ones. Clinical research raises profound ethical and safety questions. The protection of participants in a clinical trial is of paramount importance. As a consequence, clinical research is highly regulated. To facilitate collaborations across borders, many aspects of this regulation are harmonized at the European level but also worldwide.
  • Track 3-1Symptomatic heart failure: Randomized trials
  • Track 3-2Randomized trials for coronary heart diseases
  • Track 3-3Meta analysis of behaviour therapy for chronic pain
  • Track 3-4First line treatment for metastatic colorectal cancer
  • Track 3-5Design for predictive bio marker validation
  • Track 3-6Efficacy of clozapine in schizophrenic inpatients
  • Track 3-7Randomized placebo- controlled trials
Clinical study design is the formulation of trials and experiments, as well as observational studies in medical, clinical and other types of research involving human beings. The goal of a clinical study is to assess the safety, efficacy, and / or the mechanism of action of an investigational medicinal product, or new drug or device that is in development, but potentially not yet approved by a health authority. Design-based research is a type of research methodology commonly used by researchers in the learning sciences. Within design-based research methodology, interventions are conceptualized and then implemented iteratively in natural settings in order to test the ecological validity of dominant theory and to generate new theories and frameworks for conceptualizing learning, instruction, design processes, and educational reform. Types of Study Designs Meta-Analysis, Systematic Review, Randomized Controlled Trial, Cohort Study, Comparative Study, Case-control Study, Cross-sectional study, Case Reports and Series, Animal Research Studies, Test-tube Lab Research.
  • Track 4-1Design and end points of clinical trials
  • Track 4-2Phase II study of receptor enhanced chemo sensitivity
  • Track 4-3Design based research and technology
  • Track 4-4Micro RNA-21 as antiapoptotic factor for glioblastoma cells in humans
  • Track 4-5Epidermal growth factor receptor leading to lung cancer
  • Track 4-6Multi target inhibitor of vascular endothelial growth factor receptor
  • Track 4-7Role of glucose fatty-acid cycle in insulin sensitivity
  • Track 4-8Baroreflex as autonomic markers for heart-rate variability
Molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy (and thus distinguished from chemotherapy, that is, cytotoxic therapy). However, the modalities can be combined, antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy. Here are some targeted trials done so far for breast cancer, multiple myeloma, lymphoma, prostate cancer, melanoma and other cancers.
  • Track 5-1Tyrosin kinases as an activator of anti-apoptotic Ras signalling cascade
  • Track 5-2Platinum based cancer therapy
  • Track 5-3In vivo molecular target assessment
  • Track 5-4Effect of mutation in protein tyrosine phosphatase gene
  • Track 5-5Protein EZH2 leading to progression of prostate cancer
  • Track 5-6Protooncogene bcl-2 expression in the prostate cancer
  • Track 5-7α-Synuclein Gene mutation leading to Parkinson disease
  • Track 5-8Tau protein as a therapeutic target in Alzheimer disease
  • Track 5-9Stent thrombosis in randomized clinical trials
Over the past 30 years, treatment of breast cancer has greatly improved due to lessons learned through clinical trials. Clinical trials test the safety and benefits of new treatments, diagnostic methods and screening tests. People volunteer to take part in these research studies. Whether a new therapy or test becomes part of standard treatment (or diagnosis or screening) for breast cancer depends largely on clinical trial results. For example, clinical trials showed the benefit of hormone therapies and trastuzumab (Herceptin) in breast cancer treatment and these drugs are now part of standard care. Large randomized clinical trials are viewed as the best basis for making treatment guidelines. Clinical trials take place around the world in many types of medical centers and hospitals. Often, trials are funded by a agencies like the National Cancer Institute.
  • Track 6-1Phase II trial of HER-2/neu proto-oncogene in breast cancer
  • Track 6-2Tamoxifen and breast cancer
  • Track 6-3Trials for women with node-negative, estrogen positive breast cancer
  • Track 6-4BRCA2 as breast cancer susceptible gene
  • Track 6-5CXCR4 and CCR7 expression in human breast cancer cells
  • Track 6-6Radiotherapy: Alternate for mastectomy in case of ductal carcinoma
  • Track 7-1Randomized and non-randomized clinical trials
  • Track 7-2Accurately forecasting the timelines of trials
  • Track 7-3Balancing CRO-sponsors responsibility
  • Track 7-4Antiplatelet therapy for myocardial infraction
  • Track 7-5Osteoprotegerin as a ligand for osteoclast
  • Track 7-6Beta-amyloid precursor protein mutation in familial Alzheimer disease
  • Track 8-1International trial coordination
  • Track 8-2Current and future trends in outsourcing and alliance to keep ahead of competition
  • Track 8-3Incorporating New Media Tools in the Design and Conduct of Clinical Trials
  • Track 8-4Creating new business opportunities at operational level
  • Track 8-5Intellectual property provisions in clinical trials agreements
  • Track 8-6Landmines in clinical trials
  • Track 8-7Managing quality in outsourced clinical trials
  • Track 8-8Clinical trial agreements outside USA
With the increasing challenges associated with bringing a medical product to market, and skyrocketing R&D costs, there has been a shift in biopharmaceutical commercialization and clinical trial strategies in order to minimize risk and maximize success. It is estimated that bringing medical products to market costs $1.3 billion and 1 out of every 5000 experimental compounds achieve FDA approval. Moreover, market saturation in many disease modalities is also forcing biopharmaceutical enterprises to focus their efforts on accessing patients with orphan/rare diseases.
  • Track 9-1Emerging breakthroughs
  • Track 9-2Modification of adaptive design
  • Track 9-3Trial design: formulation development, manufacturing and analytical testing
  • Track 9-4Economics in clinical trials
  • Track 9-5Cloud based medical image management for clinical trials
  • Track 9-6Outsourcing of technologies
  • Track 10-1Bioethics: protection of human subjects
  • Track 10-2Ethical regulatory guidelines
  • Track 10-3Capacity building in clinical research
  • Track 10-4Bioethics: Case studies